Rani Therapeutics Net Worth
Rani Therapeutics Net Worth Breakdown | RANI |
Rani Therapeutics Net Worth Analysis
Rani Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Rani Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Rani Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Rani Therapeutics' net worth analysis. One common approach is to calculate Rani Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Rani Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Rani Therapeutics' net worth. This approach calculates the present value of Rani Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Rani Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Rani Therapeutics' net worth. This involves comparing Rani Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Rani Therapeutics' net worth relative to its peers.
To determine if Rani Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Rani Therapeutics' net worth research are outlined below:
| Rani Therapeutics generated a negative expected return over the last 90 days | |
| Rani Therapeutics has high historical volatility and very poor performance | |
| Rani Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (33.97 M) with profit before overhead, payroll, taxes, and interest of 2.72 M. | |
| Rani Therapeutics Holdings currently holds about 98.17 M in cash with (51.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Rani Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: RANI Third Quarter Update |
Rani Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Rani Therapeutics Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rani Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Rani Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rani Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rani Therapeutics Holdings backward and forwards among themselves. Rani Therapeutics' institutional investor refers to the entity that pools money to purchase Rani Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lasry Marc | 2024-06-30 | 62.9 K | Motco | 2024-09-30 | 48.1 K | State Street Corp | 2024-06-30 | 42 K | Renaissance Technologies Corp | 2024-09-30 | 33.2 K | Brown Advisory Holdings Inc | 2024-09-30 | 32.9 K | Citadel Advisors Llc | 2024-09-30 | 26.9 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 21.2 K | Lafayette Investments, Inc. | 2024-06-30 | 19.9 K | Tower Research Capital Llc | 2024-06-30 | 14.4 K | Armistice Capital, Llc | 2024-09-30 | 2.6 M | Vanguard Group Inc | 2024-09-30 | 709.8 K |
Follow Rani Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 116.52 M.Market Cap |
|
Project Rani Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (1.32) | (1.39) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (2.64) | (2.51) |
When accessing Rani Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Rani Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Rani Therapeutics' profitability and make more informed investment decisions.
Evaluate Rani Therapeutics' management efficiency
Rani Therapeutics has return on total asset (ROA) of (0.5683) % which means that it has lost $0.5683 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2535) %, meaning that it created substantial loss on money invested by shareholders. Rani Therapeutics' management efficiency ratios could be used to measure how well Rani Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.62. The current Return On Capital Employed is estimated to decrease to -1.39. As of now, Rani Therapeutics' Fixed Asset Turnover is increasing as compared to previous years. The Rani Therapeutics' current Asset Turnover is estimated to increase to 0.03, while Non Current Assets Total are projected to decrease to under 6.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.00 | 1.05 | |
| Tangible Book Value Per Share | 1.00 | 1.05 | |
| Enterprise Value Over EBITDA | (1.67) | (1.75) | |
| Price Book Value Ratio | 6.58 | 6.91 | |
| Enterprise Value Multiple | (1.67) | (1.75) | |
| Price Fair Value | 6.58 | 6.91 |
Leadership effectiveness at Rani Therapeutics Holdings is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 84.2765 | Quarterly Revenue Growth (1.00) | Return On Equity (2.25) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rani Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rani Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rani Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rani Therapeutics Corporate Filings
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 16th of October 2024 Other Reports | ViewVerify | |
| 17th of April 2024 Other Reports | ViewVerify |
Rani Therapeutics Earnings per Share Projection vs Actual
Rani Therapeutics Corporate Management
| Alireza Javadi | Vice Operations | Profile | |
| Svai Sanford | Chief Officer | Profile | |
| Mir Hashim | Chief Officer | Profile | |
| Arvinder Dhalla | Vice Development | Profile | |
| Bella Vazquez | Vice Resources | Profile | |
| Eric Groen | General Counsel | Profile | |
| Kate MBA | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.57) | Return On Equity (2.25) |
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.